Brief Description
Acrigin Biosciences is developing Precision Gene Editing Systems to harness the power of CRISPR for use in human therapeutics. Acrigen’s proprietary technology leverages novel αCas and μCas CRISPR gene editors coupled with ErAcrs (engineered anti-CRISPR proteins) to create an editing toolbox with best-in-class efficiency and precision. The company's technology will expand the impact of CRISPR by improving the efficacy and safety of novel gene editing therapies.
Inventors
Jennifer Doudna, Christof Fellmann, Haridha Shivram, Kyle Watters
Company Founders
David Rabuka (UC Berkeley, Ph.D., Chemistry), Joseph Bondy-Denomy, Heath Lukatch (UC Berkeley, B.A., Biochemistry)
Timeline
- 2019. Company founded